Cited by 895Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsPancreatitis Pathology and Treatment

The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.

Molecular subtypes of pancreatic cancer

Open access

Collisson, Eric A., Bailey, Peter, Chang, David K., Biankin, Andrew V.·2019·Nature Reviews Gastroenterology & Hepatology

DOI 10.1038/s41575-019-0109-y

Open this paper in CoChat — free account

Abstract

Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease.

Integrity signals

Registry

Crossref · 10.1038/s41575-019-0109-y

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Cancer Statistics, 2017.
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citation
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Self-citation

Show all 119 references

Research works printed but not linked: 1

Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 2140–2141 (2014).

Sorted by citations

Items 801–895 of 895

Adaptive resistance to SHP2-based vertical RAS-pathway inhibition in pancreatic cancer involves multifaceted routes towards dedifferentiationPreprint
Chen, X., Keller, S. J., Das, T., Hafner, P., Alrawashdeh, A. Y., Jumaa, H., Chen, T., Besson, S., Norona, J., Schneider, M., et al. (2025) · medRxiv · doi:10.1101/2025.09.09.25335395
Modulating p38MAPK recalibrates sensitivity of drug-resistant pancreatic adenoductal carcinoma cells toward chemotherapy and correlate with improved outcome in PDAC patients: Experimental and metadata evidencePreprint
Mehra, V., Gandhi, K., Das, P., Sharma, G., Bhardwaj, M., Gongora, C., & Prakash, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.04.680430
Impact of SERPINA3 on the Prognostic Role of KRAS G12R‐Mutated Pancreatic Ductal Adenocarcinoma Patients Receiving Gemcitabine‐Based Treatment: A Cross‐Sectional Study
He, X., Ren, L., Dong, S., & Liu, W. (2025) · Health Science Reports · doi:10.1002/hsr2.71332
Expression of PLAU in Tumor Microenvironment of Hypoxic and Immunosuppressive Pancreatic Cancer and Its Influence on Prognosis
刘, 任. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.131100
Defining the transcriptional landscape in the classical subtype of pancreatic cancer
(2025) · Nature Genetics · doi:10.1038/s41588-025-02392-y
Tumor-intrinsic dichotomy shapes cellular heterogeneity in pancreatic cancer
Samuel, R. D., & Singh, S. K. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.11.003
Analyzing the loss of nest related phenotype and revealing the operability of pancreatic ductal adenocarcinoma through electrochemical sensor content and scRNA seq
Chen, Q., Meng, M., Ren, S., Zhang, T., Lu, J., Bing, Y., Li, L., & Yuan, C. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.116209
Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Lin, E. W., Pathak, P., O’Shea, A., Awasthi, B. W., Phillips, I. E., Kocher, J. R., Song, Y., Raabe, M. J., Xu, K. H., Patel, B. K., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2052 · Cited by 1
PRSS23 promotes pancreatic cancer progression through regulating Hippo-YAP activity
Liu, Z., Jiang, Q., Sun, Y., Song, Y., & Yu, B. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153157
Additional file 1 of Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis
Kim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S.-H., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25123881
Additional file 1 of IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma
魏蓉, Qi, G., Zeng, Z., Shen, N., Wang, Z., Shen, H., Gao, L., Song, C., Ma, W., & Wang, C. (2021) · Figshare · doi:10.6084/m9.figshare.17079497
Additional file 1 of The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
Shui, L., Li, X., Peng, Y., Tian, J., Li, S., He, D., Li, A., Tian, B., Li, M., Gao, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14956007
Additional file 1 of Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
Li, E., Huang, X., Zhang, G., & Liang, T. (2021) · Figshare · doi:10.6084/m9.figshare.16570249
Additional file 2 of PancrESS – a meta-analysis resource for understanding cell-type specific expression in the human pancreas
Sturgill, D. M., Wang, L., & Arda, H. E. (2024) · Figshare · doi:10.6084/m9.figshare.25026016
Additional file 3 of Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer
Göhrig, A., Hilfenhaus, G., Rosseck, F., Welzel, M., Moser, B., Barbone, G., Kunze, C. A., Rein, J., Wilken, G., Böhmig, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26727466
Additional file 6 of Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer
Göhrig, A., Hilfenhaus, G., Rosseck, F., Welzel, M., Moser, B., Barbone, G., Kunze, C. A., Rein, J., Wilken, G., Böhmig, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26727475
Additional file 1 of Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature
Li, Q., Feng, T., Zhu, T., Zhang, W., Qian, Y., Zhang, H., Zheng, X., Li, D., Yun, X., Zhao, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26576051
Additional file 4 of PancrESS – a meta-analysis resource for understanding cell-type specific expression in the human pancreas
Sturgill, D. M., Wang, L., & Arda, H. E. (2024) · Figshare · doi:10.6084/m9.figshare.26669244
Additional file 3 of Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis
Kim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S.-H., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26675240
Additional file 1 of A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma
Chen, Y., Lin, X., Zou, X., Qian, Y., Liu, Y., Wang, R., Wang, X., Yu, X., Liu, C., & Cheng, H. (2023) · Figshare · doi:10.6084/m9.figshare.22623973
Additional file 1 of DECONbench: a benchmarking platform dedicated to deconvolution methods for tumor heterogeneity quantification
Decamps, C., Arnaud, A., Petitprez, F., Ayadi, M., Baurès, A., Armenoult, L., Escalera, S., Guyon, I., Nicolle, R., Tomasini, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16726873
Additional file 8 of Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer
Göhrig, A., Hilfenhaus, G., Rosseck, F., Welzel, M., Moser, B., Barbone, G., Kunze, C. A., Rein, J., Wilken, G., Böhmig, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26727481
Additional file 2 of Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature
Li, Q., Feng, T., Zhu, T., Zhang, W., Qian, Y., Zhang, H., Zheng, X., Li, D., Yun, X., Zhao, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26576054
Additional file 2 of Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis
Kim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S.-H., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25124095
Additional file 7 of Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer
Göhrig, A., Hilfenhaus, G., Rosseck, F., Welzel, M., Moser, B., Barbone, G., Kunze, C. A., Rein, J., Wilken, G., Böhmig, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26727478
Additional file 1 of Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy
Liu, J., Liu, Q., Zhang, X., Cui, M., Li, T., Zhang, Y., & Liao, Q. (2021) · Figshare · doi:10.6084/m9.figshare.14129385
Additional file 1 of Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer
Göhrig, A., Hilfenhaus, G., Rosseck, F., Welzel, M., Moser, B., Barbone, G., Kunze, C. A., Rein, J., Wilken, G., Böhmig, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25940025
Additional file 4 of Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer
Göhrig, A., Hilfenhaus, G., Rosseck, F., Welzel, M., Moser, B., Barbone, G., Kunze, C. A., Rein, J., Wilken, G., Böhmig, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26727469
Additional file 1 of [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma
Harder, F. N., Jungmann, F., Kaissis, G. A., Lohöfer, F. K., Ziegelmayer, S., Havel, D., Quante, M., Reichert, M., Schmid, R. M., Demir, İ. E., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15071563
Additional file 3 of PancrESS – a meta-analysis resource for understanding cell-type specific expression in the human pancreas
Sturgill, D. M., Wang, L., & Arda, H. E. (2024) · Figshare · doi:10.6084/m9.figshare.26669241
Additional file of Circular RNA CDR1as promotes tumor progression by regulating miR-432-5p/E2F3 axis in pancreatic cancer
Xiong, X., Feng, J., Yang, X., Li, H., Shi, Q., Tao, J., & Chang, J. (2021) · Figshare · doi:10.6084/m9.figshare.14432309
Additional file 1 of ROR1 and ROR2 expression in pancreatic cancer
Liu, D., Sharbeen, G., Phillips, P., & Ford, C. E. (2021) · Figshare · doi:10.6084/m9.figshare.16994428
Additional file 5 of Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer
Göhrig, A., Hilfenhaus, G., Rosseck, F., Welzel, M., Moser, B., Barbone, G., Kunze, C. A., Rein, J., Wilken, G., Böhmig, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26727472
Additional file 1 of PancrESS – a meta-analysis resource for understanding cell-type specific expression in the human pancreas
Sturgill, D. M., Wang, L., & Arda, H. E. (2024) · Figshare · doi:10.6084/m9.figshare.25025849
Additional file 2 of Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer
Göhrig, A., Hilfenhaus, G., Rosseck, F., Welzel, M., Moser, B., Barbone, G., Kunze, C. A., Rein, J., Wilken, G., Böhmig, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25940205
Chirurgische Therapie des Pankreaskarzinoms
Tjaden, C., Hackert, T., & Büchler, M. (2024) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_553-2
Spatial Transcriptomics in Pancreatic Cancer: Current Insights and Future Directions
Kim, J. S. (2025) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2025.13.3.288
The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy
Wang, H., Li, Y., Tang, S., Li, Y., Zhang, Y., Yin, X., He, J., Zhu, Y., Zhang, Y., Shi, X., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218252
Exploring the Pathogenesis and Treatment of Pancreatic Cancer Tumor Microenvironment Based on “Deficiency, Phlegm, Toxicity, and Blood Stasis”
黄, 心. (2026) · Traditional Chinese Medicine · doi:10.12677/tcm.2026.152067
Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden‐High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment
Kai, Y., Ikezawa, K., Kozumi, K., Urabe, M., Takada, R., Kinomoto, T., Masumoto, T., Kawabata, M., Kishimoto, H., Hosokawa, K., et al. (2026) · Cancer Reports · doi:10.1002/cnr2.70492
Endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling
Okuno, N., & Hara, K. (2026) · Choonpa Igaku · doi:10.3179/jjmu.jjmu.r.269
Integrative Transcriptomic and Proteomic Profiling Defines Secretory and Immune Related Subtypes in Pancreatic Ductal Adenocarcinoma
Lin, S., Yao, X., Guo, P., Shi, H., Luo, H., Ke, K., Teng, T., & Weng, S. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c01146
Using machine learning to predict and analyze complex trait diseases: Lessons from a simple abstract model
Maimon, E., Bondi, O., Moult, J., & Unger, R. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342490
Personalized signaling pathway analysis of gastrointestinal tumors for patient stratification and drug target evaluation using clinically derived core biopsies
Stahl, A., Büringer, K., Missios, P., Hoffmann, T., Mattern, S., Singer, S., Schäfer-Ruoff, F., MALEK, N. P., Schenke‐Layland, K., Bitzer, M., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01304-5
Extracellular vesicle-encapsulated microRNA-425 promotes tumor development and serves as a biomarker for pancreatic ductal adenocarcinoma
Koyama, K., TAKAHASHI, K., Yusuke, O. N. O., Oyama, K., Tamamura, N., Tanaka, H., Asai, F., Kobayashi, Y., Maeda, C., Ohtaki, Y., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02382-9
NR3C1 , LAX1 , and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metastatic Pancreatic Cancer
Cano-Ramírez, P., Toledano‐Fonseca, M., Cano‐Osuna, M. T., Herrera‐Casanova, N. M., Carrillo‐Pecero, E., Rodríguez‐Ariza, A., Aranda, E., & García‐Ortiz, M. V. (2026) · MedComm · doi:10.1002/mco2.70682
Fonctions oncogéniques de la phospholipase A2α cytoplasmique au cours de la progression tumorale pancréatique
Olmedo, C. (2019) · theses.fr (ABES) · doi:10.70675/0455a20dz4de2z4a92z88b2z6295a7f90fb3
Targeting mitochondrial metabolism in pancreatic cancer
Reyes‐Castellanos, G. (2021) · theses.fr (ABES) · doi:10.70675/461953f3z886ez4342za1e2z84c44a9fcaa6
Exploring PI3K signalling dynamics in pancreatic cancer
Delgado, C. F. R. (2020) · theses.fr (ABES) · doi:10.70675/6df9a059zc3f1z4997z9de2z34a1d24dfbeb
Impact du dialogue entre microenvironnement et cellules cancéreuses dans l'adénocarcinome canalaire pancréatique
Nigri, J. (2020) · theses.fr (ABES) · doi:10.70675/8e941da5z4553z4ca3zaf8az9ac2c39c788a
Utilisation des gènes de glycosyltransférases pour stratifier les patients atteints d'adénocarcinome pancréatique : identification d'une glyco-signature pronostique et biomarqueurs associés
Abd-El-Halim, Y. M. (2021) · theses.fr (ABES) · doi:10.70675/7a02077czfc19z45f2z92f0ze2f11ebce9fd
Characterisation of SG33 Myxoma virus replication and oncolytic activity in pancreatic cancer models
Quillien, L. (2021) · theses.fr (ABES) · doi:10.70675/eadfa28azee41z4b56z88f3zc40b7ff9f900
Chimiorésistance du cancer du pancréas : rôle de la transition épithéliomésenchymateuse et les voies de signalisation impliquées
Amrani, M. E. (2019) · doi:10.70675/494ef387z9f8bz4a29z9028z9325932bac94
Elucidation du rôle de la Ténascine-X dans la progression tumorale : focus sur la carcinogenèse pancréatique
Liot, S. (2021) · theses.fr (ABES) · doi:10.70675/264bf0e9z97a7z4aaezaf51z5387f0dd8f4c
Identification et ciblage de dialogues tumeur-stroma impliqués dans l'agressivité de l'adénocarcinome canalaire pancréatique
Brunel, A. (2022) · theses.fr (ABES) · doi:10.70675/4f9e08fez29b2z4a0dzabf6z424c6decb590
Targeting mitochondrial and redox metabolism to prevent relapse in pancreatic cancer
Hadi, N. A. (2022) · theses.fr (ABES) · doi:10.70675/de0db041z7be5z4ee3z8a2cz7ca2e21ede31
Role of hematological parameters in pancreatic cancer: A literature review
Jamil, T., Anis, K., Rehman, A., Iqbal, S., Pervaiz, S., Latif, M. I., Hafeez, R., Khurshid, H., & Rafaqat, S. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i4.117765
Stroma-nerve axis in pancreatic ductal adenocarcinoma: Bidirectional regulatory mechanisms and clinical translation hypothesis
Yu, Y.-N., Jin, S.-Q., Lu, Y.-T., & Han, L.-Z. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.v17.i4.117197
Interleukin-1α (IL-1α) in pancreatic ductal adenocarcinoma: implications for immunotherapy and molecular biomarkers
Ling, K., Xie, G., Chen, Z., Da, M., & Qiu, Z. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04325-5
Immunotherapy in pancreatic cancer: overcoming the challenges of tumor heterogeneity
Nakamura, M., He, Z., Dhulia, R., Manji, G. A., & Reya, T. (2026) · Trends Open · doi:10.1016/j.treopn.2026.04.001
Molecular Subtypes of Pancreatic Cancer: A Review of the Literature
Wnuk, J. S., Skowron, W., Długaszek, A., Sadurska, J., Pietrzyński, Ł., Kabut, J., & Gisterek, I. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48050502
Letter to the Editor: Beyond anatomical modeling: Integrating biological and radiomic insights to improve portal-systemic venous invasion prediction
Park, S. Y., & Chon, H. K. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.116974
P38MAPK targeting in pancreatic ductal adenocarcinoma: Promising interventional approach for breaking drug resistance and tumor control
Mehra, V., Gandhi, K., Freixinos, C., Das, P., Dash, N. R., Sharma, G., Bhardwaj, M., Gongora, C., & Prakash, H. (2026) · Medical Oncology · doi:10.1007/s12032-026-03299-2
An integrative mutational and network analysis of pancreatic cancer reveals key genes, and signalling pathways
Manjunath, G. K., Kanchi, L. P., Dakal, T. C., Beura, A., & Kumar, A. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01921-0
How mutation-driven predisposition shapes the accelerated adaptive trajectory of SARS-CoV-2: the role of NSP4 T492I
Li, Y., Zeng, J., Jiang, C., Leng, L., & Zhu, Z. (2026) · Future Virology · doi:10.1080/17460794.2026.2688750
Mesopancreas excision in pancreatic ductal adenocarcinoma: recurrence patterns — a single-arm descriptive study
Saleh, S. K., Saleh, A. G., Mohamed, T. A., Hendy, M. M., Farahat, M. S., Boushera, S. T., Kamil, C. M., & Saleh, R. K. (2026) · World Journal of Surgical Oncology · doi:10.1186/s12957-026-04459-4
Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large‐Cohort Study
You, T. T., Tang, H., Yuan, M., Song, D., Wang, C., Ying, J., Chen, R. R., Bai, C., Cheng, Y., & Wang, Y. (2026) · MedComm · doi:10.1002/mco2.70829 · Cited by 1
Letter to the Editor: Beyond anatomical modeling: Integrating biological and radiomic insights to improve portal-systemic venous invasion prediction
Park, S. Y., & Chon, H. K. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.116974
Aptamer-based inhibition of MNK1 reduces pancreatic ductal adenocarcinoma growth by targeting cancer stem cells
Pérez‐Ruíz, A., Ruiz-Cañas, L., Batres, S., Ferreras-Martín, R., Pinto‐Díez, C., Yagüe, B., Pérez-Morgado, M. I., Sacristán, S., Ruz‐Caracuel, I., Páez, S. C., et al. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01275-6
Investigating the anticancer activity of eravacycline in pancreatic cancer via target-based deep learning and experimental validation
Jabarin, A., Shtar, G., Feinshtein, V., Mazuz, E., Shapira, B., Rokach, L., & Ben‐Shabat, S. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag353
Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody–Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan
Kawczak, P., Kawczak, K., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145521
Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection
Okabayashi, T., Tabuchi, M., Tokumaru, T., Uemura, S., & Tamura, S. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2709779
Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective randomized controlled phase 2 trials (Prodige35, Prodige37 and AFUGEM)
Zhao, S., Nicolle, R., Taı̈eb, J., Dahan, L., Abdallah, R., Bouché, O., Desrame, J., Phelip, J., Evesque, L., Akouz, F. K., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218745
U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoint integrity
Panzeri, V., Pieraccioli, M., Ruta, V., Manno, M. V., Caggiano, C., Hartem, D., Riente, A., Milletti, G., Quero, G., Alfieri, S., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03795-3
177Lu-FAP-2286 Targeted Radionuclide Therapy in Advanced Pancreatic Cancer
Xu, T., Tian, C., Yang, H., Luo, A., Zheng, W., Mou, L., & Chen, Y. (2026) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006615
Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition
Botta, G. P., Edwards, W. F., Nishizaki, D., Hargreaves, D. C., Kato, S., & Kurzrock, R. (2026) · iScience · doi:10.1016/j.isci.2026.116772
Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses
Gupta, M., Choi, H., Karasic, T. B., Furth, E. E., Shaffer, S. M., Englander, S., Pickup, S., Clendenin, C., Liu, F., Cao, Q., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0443
Rethinking PDAC: from immunological silence to therapeutic opportunity
Kali, S. K., Ramesh, R. P. G., Alam, A., Fernández-Cabezudo, M. J., Al-Awadhi, A. M., Kishore, U., & al-Ramadi, B. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1909191
Tumors exploit interclonal Hedgehog-Wnt crosstalk to drive tumor-promoting cell competition
Kong, D., Lin, P., Guo, Y., Lin, K., Zhao, S., Yang, S., Wang, X., Zhu, G., Xie, L., Tatekawa, S., et al. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.07.018 · Cited by 1
Targeting ferroptosis to overcome drug resistance in gastrointestinal cancers
Cao, C., Qi, H., Qian, W., Xing, Y., Ma, X., Wang, Y., Chu, Y., & Jia, Y. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04550-y
ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer
Shi, X., Yin, X., Gao, S., Wu, X., Wang, H., Wang, B., Xu, X., Zheng, K., Wei, J., Li, G., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117479
A serpin–myeloid axis in pancreatic cancer heterogeneity and immune evasion
Falcomatà, C., Schaefer, M. M., Singh, B., Chhamalwan, D., Tepper, A., Nielsen, S. R., Potak, H. T., Dhainaut, M., Mollaoglu, G., Park, M. D., et al. (2026) · Nature · doi:10.1038/s41586-026-11002-8
Immunomodulatory impact of PTPN11 /SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancerPreprint
Alrawashdeh, A. Y., Chen, X., Hafner, P., Keller, S. J., Das, T., Jumaa, H., Avery, T. Y., Besson, S., Hempel, S., Mewes, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.23.727401
Clinical Significance of a Cell‐Of‐Origin‐Based Classification in Pancreatic Ductal Adenocarcinoma
Kikuchi, T., Ako, S., Kato, H., Kinugasa, H., Uchida, M., Oda, T., Hirai, R., Matsumi, A., Miyamoto, K., Terasawa, H., et al. (2026) · Cancer Science · doi:10.1111/cas.70533
Targeting the DNA Damage Response in Cancer
Qiao, Y., Kang, B., Zhang, J., Zhang, R., & Li, J. (2026) · MedComm · doi:10.1002/mco2.71020
A modified CAP-based grading system incorporating non-tubular components for prognostic stratification in pancreatic ductal adenocarcinoma
Sano, N., Ikeda, E., Ando, K., Kabasawa, S., Sakaguchi, M., Numakura, S., Kanno, A., Sasanuma, H., Kawata, H., & Fukushima, N. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04731-8
Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cellsPreprint
Hawthorne, K., Eng, J. R., Tsuda, M., Worth, P. J., Fields, A. J., Daniel, C. J., Nishida, A., Pelz, C., Langer, E. M., Waugh, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.28.754674
Transcription factor-driven metabolic stratification reveals glycolytic and lipogenic subtypes with distinct prognostic and functional features in pancreatic cancer
Ke, J., Liu, S., Xu, J., & Wu, F. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1900370
High SMAD4 Expression is Associated With Improved Clinical Outcomes in Patients With Resectable Pancreatic Cancer: An Analysis of NRG Oncology/RTOG 9704
Williams, T. M., Moughan, J., Regine, W. F., Timmers, C. D., Robb, R. N., Cui, T., DiPetrillo, T. A., Leasure, N. C., Kim, H., Doncals, D. E., et al. (2026) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.09.014
Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance
Zhou, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1955015
Navigating the Pancreatic Duct: Up-to-Date Radiologic Expedition through Intraluminal Pathologic Entities
Tirukkovalur, N. V., Katabathina, V. A., Tammisetti, V. S., Jalluri, G. D., Ngan, K.-K., Borhani, A. A., & Dasyam, A. K. (2026) · Radiographics · doi:10.1148/rg.250207
Dataset related to article "Multiplexed Imaging Mass Cytometry Analysis in Preclinical Models of Pancreatic Cancer"
Erreni, M., Fumagalli, M. R., Zanini, D., Candiello, E., Tiberi, G., Parente, R., D’Anna, R., Magrini, E. I., Marchesi, F., Cappello, P., et al. (2025) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.15005850
Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis_Spatial H&E images
Kim, S., Galam, L., Choi, J., Park, J.-E., Kang, C. M., & Bang, S. (2024) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.10821762
miR-221 and miR-222 in Pancreatic Ductal Adenocarcinoma: Mechanistic Evidence, Extracellular Vesicle Communication, Biomarker Candidates, and Therapeutic Prospects
Oriquat, G., Abdulsahib, W. K., Jyothi, S. R., Nayak, P. P., Chauhan, A. S., Singla, S., Sead, F. F., & Polatova, D. S. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101515
KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer
Zhang, Y., Tang, S., Zhang, Y., Liu, J., Shi, X., Li, Y., Li, Y., Wang, H., Zhong, C., Sun, M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.10.003

Authors: Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V.
Affiliations: University of California, San Francisco (US)
University of Glasgow (GB)
Glasgow Royal Infirmary (GB)
Corresponding author: Biankin, Andrew V.
ORCID: Collisson, Eric A.
Bailey, Peter
Chang, David K.
Biankin, Andrew V.
Venue: Nature Reviews Gastroenterology & Hepatology
Publisher: Springer Science and Business Media LLC
Published: 2019-02-04
Volume: 16
Issue: 4
Pages: 207-220
ISSN: 1759-5045 (ISSN-L)
1759-5053
DOI: 10.1038/s41575-019-0109-y
OpenAlex: W2913268845
Cited by: 892
References: 119
Citations by year: 2026: 69 · 2025: 87 · 2024: 168 · 2023: 142 · 2022: 135 · 2021: 157 · 2020: 104 · 2019: 28
FWCI: 10.11
Type: journal article
Language: en
Open access: green
eprints.gla.ac.uk
Licence: cc-by-sa
www.springer.com/tdm (tdm)
Locations: Nature Reviews Gastroenterology & Hepatology (publishedVersion)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
Funders: Pancreatic Cancer UK (FLF2015_04_GLASGOW)
Wellcome Trust (103721/Z/14/Z)
Cancer Research UK (23526, 17263)
Medical Research Council (MR/N005813/1)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords: pancreatic cancer, molecular subtypes, molecular taxonomy, molecular subtyping, therapeutic targeting, treatment response, histological classification
MeSH terms: Clinical Decision-Making, Genetic Markers, Humans, Pancreatic Neoplasms, Prognosis, Biomarkers, Tumor, Risk Assessment, Carcinoma, Pancreatic Ductal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular subtypes of pancreatic cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks